The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer

The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prostate Cancer

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00126802

Enrollment

Registered

2005-08-05

Start date

2005-04-30

Completion date

2017-03-31

Last updated

2016-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

tomotherapy, MRSZ, high risk prostate cancer

Brief summary

Helical tomotherapy is being used to treat the prostate gland, local rates of spread and regional lymph nodes whilst sparing gross structures. The radiation to the gross disease in the prostate is hypofractionated and dose escalated. Magnetic resonance spectroscopic imaging (MRSI) is incorporated into pre- and post-treatment evaluation.

Interventions

PROCEDURETomotherapy

Standard 45 Gy in 25 fractions in 5 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

No minimum to 75 Years

Healthy volunteers

Inclusion criteria

* High risk localized prostate cancer

Exclusion criteria

* Low/intermediate risk, metastatic cancer * Patient refusal

Design outcomes

Primary

Measure	Time frame	Description
Rectal Toxicity	5 weeks	Determine the acute and late rectal toxicity of high-dose short-course hypofractionated radiotherapy in five weeks in the treatment of high rish prostate cancer.

Secondary

Measure	Time frame	Description
prostate-specific antigen (PSA) and MRSI disease control	3 years	Determine the biochemical control (freedom from PSA failure) rate, overall and disease free survival.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026